This Pair Should Be Together on Valentine’s Day: Biologics and Small-Molecule Medicines

The Inflation Reduction Act subjects “large-molecule” biologic therapies to price controls 13 years after FDA approval, but "small-molecule" medicines are subject to price controls after only 9 years.

This lack of parity between small molecules and biologics is undermining patient care by limiting access to affordable drugs, shifting investment to costlier treatments, and hindering pharmaceutical innovation.

Fixing the IRA to put small-molecule and biologic drugs on the same 13-year timeline would ensure patients can get the most effective and convenient treatment options.

Valentine’s Day is a reminder that it’s time to bring this pair together.

It’s time for Congress to Fix the Biden Pill Penalty.